Filing Details
- Accession Number:
- 0001453687-24-000134
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-18 19:35:50
- Reporting Period:
- 2024-11-14
- Accepted Time:
- 2024-11-18 19:35:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1453687 | Cartesian Therapeutics Inc. | RNAC | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1055624 | A Timothy Springer | 36 Woodman Road Chestnut Hill MA 02467 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-11-14 | 74,157 | $16.19 | 8,097,923 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2024-11-14 | 22,242 | $16.97 | 8,120,165 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2024-11-15 | 277,246 | $17.09 | 8,397,411 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2024-11-18 | 38,114 | $17.96 | 8,435,525 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2024-11-18 | 20,181 | $18.42 | 8,455,706 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 330,695 | Indirect | By wife |
| Common Stock | 529,798 | Indirect | See Footnote |
Footnotes
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.65 to $16.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.71 to $17.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.61 to $17.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.32 to $18.315. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.32 to $18.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
Billionaire Hedge Funds
